London close: Stocks mixed in quiet post-Christmas trade
27th Dec 2024 14:38
(Sharecast News) - London markets closed on a mixed note Friday in subdued trading, as the ongoing holiday period kept activity light with little news to influence sentiment.
Read moreAstraZeneca pulls EU application for cancer drug
24th Dec 2024 07:09
(Sharecast News) - AstraZeneca has pulled its European marketing authorisation application for its non-small cell lung cancer treatment based on the results of a phase III trial.
Read moreAstraZeneca lung cancer drug Tagrisso approved by EU regulators
23rd Dec 2024 07:17
(Sharecast News) - AstraZeneca's lung cancer treatment Tagrisso has been approved by European Union regulators on the back of "powerful results" from a phase III trial.
Read moreAstraZeneca cancer drug secures US approval
5th Dec 2024 08:48
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
Read moreAstraZeneca appoints Iskra Reic as vice-president of intl unit
4th Dec 2024 14:00
(Sharecast News) - AstraZeneca said it had appointed AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and driving sustainable growth across this broad region. This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. as executive vice-president of its international division with responsibility for overall strategy and driving sustainable growth across China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Read moreAstraZeneca reports positive results from prostate cancer trial
25th Nov 2024 07:17
(Sharecast News) - AstraZeneca announced positive results from a phase three prostate cancer trial on Monday, reporting that its AKT inhibitor 'Truqap', or capivasertib, in combination with abiraterone and androgen deprivation therapy (ADT), significantly improved radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
Read moreAstraZeneca's Tagrisso recommended for EU approval
18th Nov 2024 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended median progression-free survival to more than three years.
Read moreSunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
17th Nov 2024 18:14
(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike targets within the Kursk region, the New York Times reported. Speculation may increase that permission from Britain, the US and France to do the same with Storm Shadow missiles could follow. Joe Biden's decision is said to have been triggered by the appearance of North Korean troops in the Kursk region. - The Sunday Telegraph
Read moreDirector dealings: AstraZeneca CEO ups stake
15th Nov 2024 16:11
(Sharecast News) - AstraZeneca revealed on Friday that chief executive officer Pascal Soriot had acquired 20,000 ordinary shares in the FTSE 100-listed drugmaker.
Read moreLondon close: Stocks end turbulent week in the red
15th Nov 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
Read moreLondon close: Stocks sink as UK jobless rate rises
12th Nov 2024 16:39
(Sharecast News) - London stocks fell sharply on Tuesday as investors digested recent UK employment data alongside broader market reactions to Donald Trump's US presidential victory last week.
Read moreAstraZeneca upgrades full-year guidance amid strong momentum
12th Nov 2024 07:17
(Sharecast News) - AstraZeneca upgraded its full-year revenue and earnings per share guidance on Tuesday, citing strong growth across key therapy areas and robust financial results for the first nine months of the year.
Read moreAstraZeneca "excited" by positive results in Tezspire clinical trial
8th Nov 2024 07:19
(Sharecast News) - AstraZeneca has announced positive high-level results from a phase III for its Texspire treatment for nasal polyps.
Read moreAstraZeneca says does not comment on media reports as shares slump
5th Nov 2024 17:18
(Sharecast News) - AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share price.
Read moreAstraZeneca China president under investigation
30th Oct 2024 13:37
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Leon Wang, the president of AstraZeneca China, was under investigation by Chinese authorities.
Read more